Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003987327 | SCV004803737 | likely pathogenic | Cerebral amyloid angiopathy, APP-related | 2024-01-24 | criteria provided, single submitter | clinical testing | Variant summary: APP c.2113C>G (p.Leu705Val) results in a conservative amino acid change located in the Amyloidogenic glycoprotein, amyloid-beta peptide (IPR013803) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251340 control chromosomes. c.2113C>G has been reported in the literature in individuals affected with Cerebral Amyloid Angiopathy, APP-Related (Moro_2012, Obici_2005) and shown to segregate with disease. These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 23143229, 16178030). ClinVar contains an entry for this variant (Variation ID: 18103). Based on the evidence outlined above, the variant was classified as likely pathogenic. |
OMIM | RCV000019731 | SCV000040029 | pathogenic | CEREBRAL AMYLOID ANGIOPATHY, APP-RELATED, PIEDMONT VARIANT | 2009-07-01 | no assertion criteria provided | literature only | |
VIB Department of Molecular Genetics, |
RCV000084565 | SCV000116701 | not provided | not provided | no assertion provided | not provided |